Wire flash
FinanceVicarious Surgical to Liquidate After Shareholder Approval
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Vicarious Surgical, a surgical robot developer that raised over $425 million from investors including Bill Gates, is shutting down after shareholders voted to wind down and liquidate the business. The company, which went public via a SPAC merger in 2021 at a $1.1 billion valuation, failed to achieve FDA regulatory authorization for its single-port surgical robot. Despite receiving breakthrough device designation from the FDA, the company faced repeated delays, canceled clinical trial plans, and burned through cash. New CEO Stephen From, appointed less than a year ago, outsourced design aspects to save money but could not secure additional funding or a buyer. The company employed 26 people as of March 2026 and plans to file for dissolution in Delaware.
Source report
Author: Susan Kelly, MedTech Dive Read Time: 2 minutes
Dive Brief
- Vicarious Surgical, a robot developer that raised over $425 million from investors including Bill Gates before its 2021 initial public offering, has obtained shareholder approval to wind down and liquidate the business.
- Shareholders voted at a special meeting Tuesday to enter into an assignment for the benefit of creditors, an alternative to bankruptcy. The process transfers a company's assets into a trust for distribution to creditors.
- Vicarious was developing a single-port surgical robot designed to "shrink the surgeon" for procedures inside the patient's abdomen. However, the company faced a series of delays in bringing the device to market and last year canceled plans for a clinical trial as it pushed to finalize the design for the commercial version of the system.
Dive Insight
Vicarious is shutting down 12 years after its founding, which began with ambitious goals to improve patient outcomes, increase surgical efficiency, and address what its founders saw as significant limitations of legacy robotic platforms. Its 2021 merger with D8 Holdings, a special purpose acquisition company (SPAC), valued the company at $1.1 billion.
The company's technology — featuring miniaturized arms and a camera inserted through a single tiny incision in the abdomen — was the first surgical robot to receive a breakthrough device designation from the Food and Drug Administration (FDA). The Waltham, Massachusetts-based company had hoped to submit a filing to the FDA for use of the robot in ventral hernia procedures as its first indication.
However, Vicarious was never able to achieve regulatory authorization for the system as it burned through cash. Less than a year ago, the company brought in Stephen From as CEO, replacing co-founder Adam Sachs.
From quickly scrapped plans for a clinical trial and outsourced some aspects of the robot's design in an effort to save money.
Vicarious moved its shares to the over-the-counter market earlier this year after receiving a delisting notice from the New York Stock Exchange.
In June, the company's board recommended that shareholders approve a plan to shutter the business, after it failed to secure additional funds or find a buyer, and as operating losses continued to mount. Vicarious employed 26 people as of March 9.
According to a securities filing, Vicarious intended to file with the Delaware Secretary of State to dissolve the company as early as Wednesday.
Recommended Reading
- Vicarious Surgical board proposes dissolving the company
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.
Source
Yahoo FinanceWestern
Part of this Story
Vicarious Surgical to Liquidate After Shareholder Approval